Zobrazeno 1 - 10
of 105
pro vyhledávání: '"Moola Joghee Nanjan"'
Autor:
Shalini, Ramalingam, Chandrasekar, Moola Joghee Nanjan, Nanjan, Moola Joghee, Madhunapantula, SubbaRao V., Karnik, Medha, Selvaraj, Jubi, Ganesh, Gonna Nandhi Krishnan
Publikováno v:
In Journal of Ethnopharmacology 28 October 2023 315
Autor:
Ramamurthi, Deepthi, Selvaraj, Jubie, Raj, P. Vasanth, Tallapaneni, Vyshnavi, Chandrasekar, Moola Joghee Nanjan
Publikováno v:
In Journal of Drug Delivery Science and Technology October 2022 76
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Mini-Reviews in Medicinal Chemistry. 23
Background: Wounds provide a favourable site for microbial infection. Wound infection makes the healing more complex and does not proceed in an orchestrated manner leading to the chronic wound. Clinically infected wounds require proper antimicrobial
Autor:
Patnaik, Sunil Kumar, Swaroop, Akey Krishna, Naik, Mudavath Ravi, Selvaraj, Jubie, Chandrasekar, Moola Joghee Nanjan
Publikováno v:
Drug Research; Jul2023, Vol. 73 Issue 6, p341-348, 8p
Autor:
Moola Joghee Nanjan Chandrasekar, Sunil Kumar Patnaik, Akey Krishna Swaroop, Palathoti Nagarjuna, Moola Joghee Nanjan
Publikováno v:
Current Molecular Pharmacology. 16
Abstract: Cancer is one of the most deadly diseases involving dysregulated cell proliferation. Chemotherapeutic drugs have serious drawbacks of nonspecific toxicity and drug resistance. Tyrosine kinases are a significant class of enzymes of protein k
Repurposing of FDA Approved Drugs and Neuropep peptides as Anticancer Agents Against ErbB1 and ErbB2
Autor:
Sunil Kumar Patnaik, Akey Krishna Swaroop, Mudavath Ravi Naik, Jubie Selvaraj, Moola Joghee Nanjan Chandrasekar
Publikováno v:
Drug Research.
ErbB1 and ErbB2 are the most important biological targets in cancer drug discovery and development of dual inhibitors for the cancer therapy. FDA approved drugs and Neuropep peptides were used to fit into the ATP binding site of the tyrosine kinases;
Autor:
Jagat C. Borah, Dhananjay Jade, Prasenjit Manna, Selvaraj Ayyamperumal, Chandrasekar Moola Joghee Nanjan, Sagar Barge, Narayan Chandra Talukdar, Moola Joghee Nanjan
Publikováno v:
Journal of Biomolecular Structure and Dynamics. 40:13799-13811
Over the years, FK506-binding proteins have been targeted for different pharmaceutical interests. The FK506-binding protein, encoded by the FKBP5 gene, is responsible for stress and metabolic-related disorders, including cancer. In addition, the FKBD
Autor:
R. Shalini, Chandrasekar Moola Joghee Nanjan, Moola Joghee Nanjan, SubbaRao V. Madhunapantula, Medha Karnik, Jubi Selvaraj, G.N.K. Ganesh
Publikováno v:
Journal of Ethnopharmacology. :116654